Velázquez-Arellano A

Language: Spanish
References: 24
Page: 633-640
PDF size: 451.71 Kb.

ABSTRACT

Two different types of vaccines were developed against poliomyelitis: The Salk vaccine using inactivated virus and the Sabin one, that was used later, after investigations assured its safety. The first one was made in Mexico with its own resources since 1957 thanks to the efforts of young researchers and technicians coordinated by Luis Gutiérrez-Villegas, M.D., who was a Clinical Pathologist, University Professor and President of the Mexican National Academy of Mexico.

REFERENCES

1. Oshinsky DM. Polio. An American story. Oxford: Oxford University Press; 2005. 342 p.

2. Paul JR. A history of poliomyelitis. New Haven: Yale University Press; 1971. 486 p.

3. Gutiérrez-Villegas L. Resultado de la vacuna contra la poliomielitis, tipo Salk, elaborada en México. Gac Med Mex. 1958;88:319-31.

4. Aguilarpico R. El Hospital Infantil de México. Gac Med Mex. 1963;93:1155-64.

5. Coqui C. El centenario de la Academia Nacional de Medicina. Un justo recuerdo. Gac Med Mex. 1964;94:303-4.

6. Gutiérrez-Villegas L. Symposium de virología. Introducción. Gac Med Mex. 1955;85:231-3.

7. Anónimo. La historia de la Industria Nacional Químico Farmacéutica México: QuimiNet; 2011. Disponible en: http://www.quiminet.com/articulos/ la-historia-de-la-industria-nacional-quimico-farmaceutica- 1949-2576101 htm

8. Gutiérrez Villegas L, Laguna J, Campillo C, et al. Estudios sobre la immunización pasiva contra la poliomielitis con globulinas homólogas. Gac Med Mex. 1952;82:423-36.

9. Gutiérrez Villegas L. Inmunología y epidemiología de las virosis. Gac Med Mex. 1955;85:243-64.

10. Judson HF. The eighth day of creation: makers of the revolution in biology. Expanded ed. Plainview, N.Y.: CSHL Press; 1996. 714 p.

11. Bodian D. Differentiation of types of poliomyelitis viruses; reinfection experiments in monkeys (second attacks). Am J Hyg. 1949;49:200-23.

12. Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science. 1949;109:85-7.

13. Salk JE. Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. J Am Med Assoc. 1953;151:1081-98.

14. Avery OT, Macleod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type Iii. J Exp Med. 1944;79:137-58.

15. Sabin AB. Present status and future possibilities of a vaccine for the control of poliomyelitis. AMA Am J Dis Child. 1953;86 301-10.

16. Broad WJ, Wade N. Betrayers of the truth. New York: Simon and Schuster; 1983. 256 p.

17. Salk JE. Vaccination against paralytic poliomyelitis performance and prospects. Am J Public Health Nations Health. 1955;45(5 Pt 1):575-96.

18. Francis T, Jr., Korns RF, Voight RB, et al. An evaluation of the 1954 poliomyelitis vaccine trials. Am J Public Health Nations Health. 1955;45(5 Pt 2):1-63.

19. Sabin AB. Oral poliovirus vaccine. History of its development and prospects for eradication of poliomyelitis. JAMA. 1965;194:872-6.

20. Offit PA. The Cutter incident, 50 years later. N Engl J Med. 2005;352:1411-2.

21. Roberts L. Polio eradication. Rethinking the polio endgame. Science. 2009;323:705.

22. Rodríguez Pérez ME. El Consejo de Salubridad General y las epidemias. México, D.F.: Secretaría de Salud, p. 167.

23. Anónimo. Instituto Nacional de Bienestar de la Niñez. El Universal. 1955, 16 de noviembre; Sect. Primera sección.

24. Wehrle PF, Leedom JM, Portnoy B, et al. Safety of Sabin oral poliovaccine strains; mass immunization program in Los Angeles County, 1962- 1963. JAMA. 1963;186:821-6.